OncoMatch/Clinical Trials/NCT06653023
Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer
Is NCT06653023 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Universal CAR-T cells and MMF Immunosuppression for hcc - hepatocellular carcinoma.
Treatment: Universal CAR-T cells · MMF Immunosuppression — This is an investigator initiated trial to assess the efficacy and safety of a GPC3-targeting CAR-T therapy (REVO-UWD-03) in the HCC and Lung Cancer. It also aims to explore the feasibility of using a novel universal CAR-T cell platform.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: GPC3 overexpression (IHC ≥1+ in ≥50% of tumor lesion area)
Immunohistochemistry (IHC) evaluation showing GPC3 expression ≥1+ in ≥50% of the tumor lesion area
Disease stage
Required: Stage III, IV, BCLC STAGE B, BCLC STAGE C, CNLC STAGE IIB, CNLC STAGE III (BCLC, CNLC)
(1) Barcelona Clinic Liver Cancer (BCLC) stage B (not amenable to hepatic surgery and/or other local therapies, or disease progression after local therapy) or stage C; (2) Or China Liver Cancer (CNLC) stage IIb or III (not amenable to hepatic surgery and/or other local therapies, or disease progression after local therapy)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
who have failed standard therapy, or for whom no standard therapy is available, or who are unsuitable for standard therapy at this stage
Cannot have received: chemotherapy
Exception: within 14 days prior to cell collection
Received chemotherapy, targeted therapy, other investigational drugs, or monoclonal antibody therapy within 14 days prior to cell collection
Cannot have received: targeted therapy
Exception: within 14 days prior to cell collection
Received chemotherapy, targeted therapy, other investigational drugs, or monoclonal antibody therapy within 14 days prior to cell collection
Cannot have received: monoclonal antibody
Exception: within 14 days prior to cell collection
Received chemotherapy, targeted therapy, other investigational drugs, or monoclonal antibody therapy within 14 days prior to cell collection
Cannot have received: investigational drug
Exception: within 14 days prior to cell collection
Received chemotherapy, targeted therapy, other investigational drugs, or monoclonal antibody therapy within 14 days prior to cell collection
Cannot have received: investigational drug
Exception: participated in another drug clinical trial within 4 weeks prior to study initiation
Participated in another drug clinical trial within 4 weeks prior to study initiation
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5 × 10⁹/L; platelets ≥80 × 10⁹/L; hemoglobin ≥9.0 g/dL
Kidney function
Serum creatinine ≤5 × ULN or eGFR ≥50 mL/min/1.73 m²
Liver function
Total bilirubin ≤5 × ULN; AST and ALT ≤5 × ULN
Cardiac function
LVEF >50%
Adequate major organ function, meeting the following criteria: Hematology: Absolute neutrophil count ≥1.5 × 10⁹/L; platelets ≥80 × 10⁹/L; hemoglobin ≥9.0 g/dL; Liver function: Total bilirubin ≤5 × ULN; AST and ALT ≤5 × ULN; Renal function: Serum creatinine ≤5 × ULN or eGFR ≥50 mL/min/1.73 m²; Coagulation: PT prolongation ≤4 seconds; Cardiac function: LVEF >50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify